SCN4B低表达预示非小细胞肺癌预后不良。

Low Expression of SCN4B Predicts Poor Prognosis in Non-small Cell Lung Cancer.

作者信息

Li Xia, Chen Weiwei, Jiang Shu, Zhang Lianlian, Huang Hua, Ji Yanan, Ni Qinggan, Ling Chunhua

机构信息

Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, PR China.

Department of General Medicine, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng, 224000, PR China.

出版信息

Curr Cancer Drug Targets. 2025;25(5):445-466. doi: 10.2174/0115680096293516240607071915.

DOI:10.2174/0115680096293516240607071915

PMID:38956906

Abstract

BACKGROUND

Sodium voltage-gated channel beta subunit 4 (SCN4B) plays a suppressive role in various tumors. However, the role of SCN4B in non-small cell lung cancer (NSCLC) is not yet clear. This study aims to investigate the expression of SCN4B in NSCLC patients and its correlation with prognosis.

METHODS

Firstly, the expression of SCN4B in non-small cell lung cancer (NSCLC) was analyzed using The Cancer Genome Atlas (TCGA) database. Then, differential expression genes (DEGs) were identified using R software. Next, DEG enrichment pathways were analyzed using the R package clusterProfiler. Protein-protein interaction networks were revealed through STRING analysis. A heatmap showed significant differential expression of SCN4B. Further analysis included examining SCN4B expression in a pan-cancer context and its correlation with 24 types of immune cells in NSCLC. Subsequently, quantitative real-time polymerase chain reaction (qRT-PCR), Western Blot, immunohistochemistry, and clinical data were used to validate SCN4B expression and prognostic value in NSCLC patients.

RESULTS

SCN4B mRNA expression in non-small cell lung cancer tissues was significantly lower than in adjacent normal tissues (p < 0.001). Clinical correlation analysis confirmed its association with clinical pathology. Gene set enrichment analysis (GSEA) and tumor immune-related analyses indicated that SCN4B is involved in NSCLC-related Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and participates in immune infiltration. qRT-PCR, Western Blot, and immunohistochemistry also confirmed that SCN4B is downregulated in NSCLC patients and is associated with poor prognosis.

CONCLUSION

SCN4B is downregulated in tumor tissues of NSCLC patients and is associated with a poor prognosis.

摘要

背景

钠电压门控通道β亚基4（SCN4B）在多种肿瘤中发挥抑制作用。然而，SCN4B在非小细胞肺癌（NSCLC）中的作用尚不清楚。本研究旨在探讨SCN4B在NSCLC患者中的表达及其与预后的相关性。

方法

首先，利用癌症基因组图谱（TCGA）数据库分析非小细胞肺癌（NSCLC）中SCN4B的表达。然后，使用R软件鉴定差异表达基因（DEG）。接下来，使用R包clusterProfiler分析DEG富集途径。通过STRING分析揭示蛋白质-蛋白质相互作用网络。热图显示SCN4B有显著差异表达。进一步分析包括在泛癌背景下检查SCN4B表达及其与NSCLC中24种免疫细胞的相关性。随后，采用定量实时聚合酶链反应（qRT-PCR）、蛋白质免疫印迹法、免疫组织化学和临床数据来验证NSCLC患者中SCN4B的表达及其预后价值。

结果

非小细胞肺癌组织中SCN4B mRNA表达显著低于相邻正常组织（p < 0.001）。临床相关性分析证实其与临床病理相关。基因集富集分析（GSEA）和肿瘤免疫相关分析表明，SCN4B参与NSCLC相关的京都基因与基因组百科全书（KEGG）途径并参与免疫浸润。qRT-PCR、蛋白质免疫印迹法和免疫组织化学也证实SCN4B在NSCLC患者中表达下调且与预后不良相关。